The FDA’s recent complete response letter (CRL) for vadadustat — an oral therapy evaluated for the treatment of anemia in patients with chronic kidney disease (CKD) — was a big surprise and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results